velneperit (S-2367) / Shionogi  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
velneperit (S-2367) / Shionogi
NCT00747929: Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet

Completed
2b
724
US
S-2367 Placebo, S-2367 800 mg, Velneperit, S-2367 1600 mg, Reduced Calorie Diet
Shionogi
Obesity
11/08
01/09
NCT00748605: Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet

Completed
2b
842
US
S-2367 Placebo, S-2367 1600 mg q.d. 54 Weeks, Velneperit, S-2367 1600 mg q.d. 60 weeks, LCD (low calorie diet), RCD (reduced calorie diet)
Shionogi
Obesity
11/08
01/09
NCT00788528: Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects

Completed
2
766
US
S-2367 (velneperit)
Shionogi
Obesity
02/10
03/10
NCT01126970: Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

Completed
2
486
US
Velneperit 400 mg, S-2367, Orlistat 120 mg, Xenical, Orlistat Placebo, Velneperit Placebo, Reduced Calorie Diet
Shionogi
Obesity
01/11
02/11

Download Options